These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37216406)

  • 1. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
    J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.
    Nguyen TT; Nhu NT; Tran VK; Viet-Nhi NK; Ho XD; Jhan MK; Chen YP; Lin CF
    Sci Rep; 2023 Jun; 13(1):9775. PubMed ID: 37328530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
    Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
    Ann Hematol; 2024 Jul; 103(7):2231-2244. PubMed ID: 37843620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
    Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis.
    Nguyen TT; Nhu NT; Tran VK; Nguyen TTH; Lin CF
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
    Bennett R; Anderson MA; Seymour JF
    J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline treatment in CLL: the case for time-limited treatment.
    Lévy V; Delmer A; Cymbalista F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):59-67. PubMed ID: 34889444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for anti-CD20 antibodies in CLL?
    Shah HR; Stephens DM
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
    Liang L; Zhao M; Zhu YC; Hu X; Yang LP; Liu H
    Ann Hematol; 2016 Sep; 95(9):1473-82. PubMed ID: 27329288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive role of NKCD56bright cells in monitoring the progression of chronic lymphocytic leukemia during treatment.
    Blachnio K; Grygalewicz B; Woroniecka R; Rygier J; Pienkowska-Grela B; Rymkiewicz G; Kawiak J
    Folia Histochem Cytobiol; 2022; 60(3):203-214. PubMed ID: 36045602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis.
    Ke L; Li S; Huang D; Wang Y
    Front Pharmacol; 2024; 15():1413985. PubMed ID: 39050755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the management of relapsed/refractory chronic lymphocytic leukemia.
    Bennett R; Seymour JF
    Blood Cancer J; 2024 Feb; 14(1):33. PubMed ID: 38378673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):216-223. PubMed ID: 33199185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.
    Rizzuto A; Pirrera A; Gigliotta E; Mancuso S; Vullo C; Camarda GM; Rotolo C; Roppolo A; Spoto C; Gentile M; Botta C; Siragusa S
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
    Lee CH; Chen PH; Lin C; Wang CY; Ho CL
    PLoS One; 2020; 15(1):e0226879. PubMed ID: 31995577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors.
    Mkhwanazi ZA; Nyambuya TM; Mfusi SA; Nkambule BB
    BMC Cancer; 2022 Nov; 22(1):1218. PubMed ID: 36434612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.